ArticleFrontiers in endocrinology2025
The comprehensive effects of high-sensitivity C-reactive protein and triglyceride glucose index on cardiometabolic multimorbidity.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Association of high-sensitivity C-reactive protein-to-hemoglobin ratio with stroke risk: A study based on the China Health and Retirement Longitudinal Study and English Longitudinal Study of Ageing cohorts.The Journal of international medical research · 2026Article
- Joint association of TyG-ABSI composite index and inflammatory score with diabetes in middle-aged and older Chinese adults: a prospective cohort study from CHARLS (2011-2020).BMC endocrine disorders · 2026Article
- Effects of adiposity, insulin resistance, and inflammation on cardiometabolic multimorbidity: insights from interaction analyses and metabolic phenotyping in the China health and retirement longitudinal study 2011-2018.Cardiovascular diabetology · 2026Article
- Comparative Analysis of Surrogate Insulin Resistance Indexes in Cardiometabolic Multimorbidity: A Cross-Sectional Study.Reviews in cardiovascular medicine · 2026Article
- The association between triglyceride glucose-frailty index and cardiometabolic multimorbidity among Chinese middle-aged and older adults: a national prospective cohort study.Cardiovascular diabetology · 2026Article
- Relationship between triglyceride glucose-waist circumference and depressive symptoms in Chinese older adults: The China health and retirement longitudinal study.Brain, behavior, & immunity - health · 2026Article
- Associations of cumulative exposure and dynamic patterns of the C-reactive protein-triglyceride-glucose index with cardiometabolic multimorbidity in middle-aged and elderly Chinese: a nationwide cohort study.BMC public health · 2026Article
- The prognostic significance of cholesterol, high-density lipoprotein and glucose (CHG) index in evaluating all-cause mortality risk in metabolic dysfunction-associated steatotic liver disease (MASLD) individuals: evidence from two cohort studies.Cardiovascular diabetology · 2026Article
- Association between hearing impairment and cardiometabolic multimorbidity among middle-aged and older adults in China.Scientific reports · 2026Article
- Association of C-reactive protein-triglycerides-glucose index-waist to height ratio and cardiometabolic multimorbidity in middle-aged and older adults: a nationwide cohort study.Cardiovascular diabetology · 2026Article
- Effect of Small Dense Low-Density Lipoprotein Cholesterol Combined With High-Sensitivity C-Reactive Protein on Cardiometabolic Multimorbidity: A National Cohort Study.Clinical cardiology · 2026Article
- Associations of eight insulin resistance-related indices and genetic risk with incident cardiometabolic multimorbidity among participants with hypertension: a large prospective cohort study.Cardiovascular diabetology · 2026Observational
- Cumulative inflammatory index and the risk of cardiometabolic multimorbidity: a prospective cohort study among middle-aged and older adults in China.Journal of health, population, and nutrition · 2026Article
- Development and validation of a cardiometabolic multimorbidity prediction model in middle-aged and older adults.Scientific reports · 2026Article
- Systemic Inflammation in Retinal Vein Occlusion and Its Role in Clinical Outcomes of Secondary Macular Edema.Journal of clinical medicine · 2026Article
- The C-reactive protein-triglyceride glucose index (CTI) predicts mortality in cardiovascular-kidney-metabolic syndrome: a dual-cohort study with machine learning validation.International journal of surgery (London, England) · 2026Article
- Association of high sensitivity C-reactive protein-triglyceride glucose index and chronic kidney disease: a cross-sectional study.Frontiers in endocrinology · 2026Article
- High-sensitivity C-reactive protein-triglyceride-glucose composite index and reduced estimated glomerular filtration rate in adults undergoing routine health examinations: a cross-sectional study.Frontiers in endocrinology · 2026Article
- The Association of C-Reactive Protein-Triglyceride Glucose Index with Major Adverse Cardiovascular Events in Patients with Acute Myocardial Infarction.Journal of inflammation research · 2026Article
- The relationship between C-reactive protein-triglyceride-glucose index and cardiovascular disease: insights from the China health and retirement longitudinal study (CHARLS).Cardiovascular diabetology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The triglyceride-glucose index (TyG index) is one of the surrogate markers of insulin resistance, and high-sensitivity C-reactive protein (hsCRP) reflects systemic inflammation. Existing studies suggest that insulin resistance or systemic inflammation may be indicative of cardiometabolic disease, but few of the existing studies have combined the TyG index and inflammation levels before assessing cardiometabolic multimorbidity. Our study data came from the China Health and Retirement Longitudinal Study (CHARLS). Participants in this data were followed for 9 years, and we used these data to conduct a long-term analysis to assess the combined effects of the TyG index and hsCRP on cardiometabolic multimorbidity in Chinese adults over 45 years of age. Purpose: To study the combined effect of TyG index and hsCRP on cardiometabolic multimorbidity in middle-aged as well as elderly Chinese. Method: The study data came from the China Health and Retirement Longitudinal Study (CHARLS), which included a total of 4,483 middle-aged and elderly participants who did not have cardiovascular metabolic diseases at baseline, which was from CHARLS 2011, and the last survey was in 2020. A total of five cardiometabolic diseases were considered in this study: diabetes, hypertension, hyperlipidemia, heart disease and stroke. A person was defined as having cardiometabolic multimorbidity when he/she had two or more cardiometabolic diseases at the same time. TyG index (median as cut-off) and hsCRP (1mg/L as cut-off) were each divided into two groups and combined into four groups (Group L-L: TyG index<median & hsCRP<1mg/L; Group H-L: TyG index>=median & hsCRP<1mg/L; Group L-H: TyG index<median & hsCRP>=1mg/L; Group H-H: TyG index>=median & hsCRP>=1mg/L). Multiple regression equations were fitted to analyse the combined influence of TyG index and hsCRP on cardiometabolic multimorbidity. Results: TyG index increases the risk of CMM events independently of hsCRP, as does the reverse. When the TyG index is elevated and hsCRP is also elevated, this condition significantly increases the danger of cardiometabolic multimorbidity in middle-aged and elderly Chinese. Conclusion: High levels of TyG index and hsCRP can enhance the danger of cardiometabolic multimorbidity in Chinese middle-aged and elderly people, and the joint use of hsCRP and TyG index assessment may be a better way to achieve primary prevention of cardiometabolic multimorbidity in Chinese middle-aged and elderly people.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.